dolutegravir-based antiretroviral therapy

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97